Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.

Vande Casteele, Niels; Feagan, Brian G; Wolf, Douglas C; Pop, Anca; Yassine, Mohamed; Horst, Sara N; Ritter, Timothy E; Sandborn, William J

Vande Casteele, Niels; Feagan, Brian G; Wolf, Douglas C; Pop, Anca; Yassine, Mohamed; Horst, Sara N; Ritter, Timothy E; Sandborn, William J.

Afiliação

Vande Casteele N; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Feagan BG; Robarts Clinical Trials, London, Ontario, Canada.
Wolf DC; Atlanta Gastroenterology Associates, Atlanta, Georgia, USA.
Pop A; UCB Pharma, Smyrna, Georgia, USA.
Yassine M; UCB Pharma, Smyrna, Georgia, USA.
Horst SN; Vanderbilt University, Nashville, Tennessee, USA.
Ritter TE; Texas Digestive Disease Consultants, Southlake, Texas, USA.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.

Inflamm Bowel Dis ; 27(8): 1346-1355, 2021 07 27.

Article em En | MEDLINE | ID: mdl-33051647

Assuntos

Doença de Crohn; Monitoramento de Medicamentos; Inibidores do Fator de Necrose Tumoral/uso terapêutico; Adalimumab; Certolizumab Pegol; Doença de Crohn/tratamento farmacológico; Humanos; Infliximab; Estudos Prospectivos; Inibidores do Fator de Necrose Tumoral/farmacocinética

Palavras-chave

antidrug antibody; certolizumab pegol; proactive TDM; reactive TDM; therapeutic drug monitoring

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn / Monitoramento de Medicamentos / Inibidores do Fator de Necrose Tumoral Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Inflamm Bowel Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google